Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
StockNews.AI · 4 hours
AI Summary
Mineralys presented post-hoc proteomic data from Launch-HTN and Advance-HTN at ENDO 2026, showing lorundrostat engages RAAS and reduces heart-failure risk biomarkers, including NT-proBNP, versus placebo. The coordinated shifts in fibrosis and hemostasis markers suggest a broad effect on HF pathways, lending biological plausibility to a potential HF benefit and reinforcing the NDA path with a Dec 22, 2026 PDUFA target date.
Sentiment Rationale
FDA NDA acceptance and a positive HF biomarker signal set up near-term upside; data are exploratory (post-hoc) but supportive of the program’s mechanism and potential approval.
Trading Thesis
Positive biomarker signals and FDA NDA timeline could push MLYS higher into year-end 2026.
Market-Moving
- NDA PDUFA date of Dec 22, 2026 sets near-term regulatory catalyst.
- Proteomics data showing HF biomarker reductions may raise confidence in lorundrostat's HF indication.
- FDA timing and topline data risk could drive fast price swings.
- Competition from other RAAS modulators may cap upside.
Key Facts
- Mineralys presented lorundrostat HF biomarker data at ENDO 2026. Post-hoc analysis suggests potential HF risk reduction.
- In 1,004 Launch-HTN/Advance-HTN patients, 12-week proteomic data show RAAS engagement. Renin up, angiotensinogen down.
- Compared with placebo, reductions in HF biomarkers including NT-proBNP observed.
- FDA accepted NDA; PDUFA target date is December 22, 2026.
- Lorundrostat inhibits aldosterone synthase; six late-stage trials support efficacy.
Companies Mentioned
- Mineralys Therapeutics, Inc. (MLYS): NDA for lorundrostat accepted; potential HF indication; regulatory catalyst ahead.
- Tanabe Pharmaceutical Corporation (N/A): Exclusive licensee for lorundrostat IP; potential milestones/payments could influence valuation.
Industry News
Industry News: regulatory and clinical data update on a late-stage hypertension program; fits near-term catalysts.